Condition

Nephropathy

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 21 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials21
Recruiting2
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

21 shown
Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)NCT06837181 · 2025-09-18
RECRUITING
Improving Renal Complications in Adolescents With Type 2 Diabetes Through REsearch Cohort Study (National iCARE Study)NCT02818192 · 2017-01-01
RECRUITING
Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxiaNCT06147232 · 2025-02-01
NOT_YET_RECRUITING
Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic NephropathyNCT06501651 · 2024-08-01
UNKNOWN
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up StudyNCT05530356 · 2022-09-30
COMPLETED
Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Cisplatin Among Egyptian Non-small Cell Lung Cancer PatientsNCT05746598 · 2020-07-01
UNKNOWN
Effects of Probiotics and Fibers on Albuminuria in Persons With Type 1 DiabetesNCT04635670 · 2020-06-29
COMPLETED
Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 DiabetesNCT04193566 · 2020-02-01
COMPLETED
Screening for Fabry Disease in Renal TransplantationNCT03886714 · 2019-03-25
TERMINATED
Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic FunctionNCT03618420 · 2018-10-01
COMPLETED
Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes StudyNCT03584217 · 2018-10-01
ACTIVE_NOT_RECRUITING
Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 DiabetesNCT03620773 · 2018-10-01
COMPLETED
The Relationship Between HHcy and Contrast-induced Nephropathy in Hypertensive Patients After Coronary Artery Diagnosis and TreatmentNCT02575092 · 2015-11-01
COMPLETED
Atrasentan Spermatogenesis and Testicular FunctionNCT02118714 · 2015-04-06
COMPLETED
Time To Complications Occurs in DiabetesNCT00969956 · 2012-04-01
TERMINATED
The Effects of Atorvastatin on the Nitrogen Oxide-system in Patients With Type 2 Diabetes and NephropathyNCT01208701 · 2010-05-01
COMPLETED
Macrovascular and Microvascular Morbidity and Mortality After Metabolic Surgery Versus MedicinesNCT06355219 · 2010-01-01
COMPLETED
A Crossover Study With Hexalacton in Patients With Type 1 Diabetes and MicroalbuminuriaNCT00843388 · 2009-03-01
UNKNOWN
VA NEPHRON-D: Diabetes iN Nephropathy StudyNCT00555217 · 2008-07-01
TERMINATED
Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes NephropathyNCT00655330 · 2008-05-01
UNKNOWN
A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes (0954-147)(COMPLETED)NCT00308347 · 1996-05-01
COMPLETED

Common interventions

Aminohippurate Sodium Inj 20%DRUG4Iohexol Inj 300 mg/mLDRUG4PlaceboDRUG3Renal BiopsyPROCEDURE3ValsartanDRUG2AtorvastatinDRUG1AtrasentanDRUG1Cisplatin injectionDRUG1Dextran 40DRUG1Enalapril Maleate and Folic Acid tablets(as the program-based antihypertension)DRUG1Enalapril Maleate Tablets(as the program-based antihypertension)DRUG1ForxigaDRUG1lisinoprilDRUG1losartanDRUG1MK0954, losartan / Duration of Treatment: mean 3.4 yearsDRUG1observational studyOTHER1PlaceboDIETARY_SUPPLEMENT1Placebo / Duration of Treatment: mean 3.4 yearsDRUG1placebo tabletDRUG1Positron Emission TomographyRADIATION1Pro-/prebiotic MixDIETARY_SUPPLEMENT1ProbucolDRUG1Sacubitril/ValsartanDRUG1Screen for α-galactosidase mutationDIAGNOSTIC_TEST1Screening for Fabry diseaseDIAGNOSTIC_TEST1

Trial status mix

COMPLETED10
UNKNOWN4
TERMINATED3
RECRUITING2
ACTIVE_NOT_RECRUITING1
NOT_YET_RECRUITING1

Phase mix

PHASE27
PHASE13
PHASE33
PHASE43
NA2
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.